I023 Evaluating the impact of ADAM10 pharmacological inhibition on cortico-striatal dysfunction in Huntington’s disease

<h3>Background</h3> Cortico-striatal dysfunction is an early pathogenic event contributing to cognitive decline in Huntington’s disease (HD). A Disintegrin and Metalloproteinase Domain-Containing Protein 10 (ADAM10) is enriched in the brain and governs excitatory synapse structure and function by shedding neuronal trans-synaptic proteins. We have previously linked ADAM10 hyperactivity and enhanced proteolysis of N-Cadherin to HD synaptic dysfunction and cognitive decline. <h3>Aim</h3> Our aim is to evaluate whether the ADAM10 inhibitor GI254023X alleviates pre- and postsynaptic defects in the HD cortico-striatal circuitry. <h3>Methods</h3> A two-compartment microfluidic system was used, together with mouse primary cortical and striatal neurons from wild-type and HD mice, to reconstruct the cortico-striatal circuitry in vitro. Immunolabelling of pre- and post-synaptic proteins was used to identify excitatory synaptic contacts. Furthermore, live-imaging microscopy was employed to monitor Brain-Derived Neurotrophic Factor (BDNF) transport. Cortical and striatal neurons were exposed to GI254023X in acute and chronic paradigms. <h3>Results</h3> We recreated the wild-type and HD cortico-striatal circuitry in microfluidic chambers. We developed an automated pipeline to quantitatively evaluate excitatory synapse density. We set up conditions to study transport dynamics of BDNF-containing vesicles in the cortical afferents. We identified GI254023X doses and exposure times that conferred neuroprotection to HD neurons. Currently, we are testing if GI254023X restores BDNF transport in HD cortical neurons. <h3>Conclusion</h3> Our findings suggest that pharmacological inhibition of ADAM10 attenuates synaptic phenotypes in the HD cortico-striatal circuitry. Future studies will evaluate the therapeutic potential of GI254023X in rescuing synaptic and cognitive abnormalities in HD mice. Funded by Telethon Foundation (#GGP20067)

Authors

Institutions

Publication Details

Published
2024-09-01
DOI
https://doi.org/10.1136/jnnp-2024-ehdn.305
Primary Topic
Genetic Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

I023 Evaluating the impact of ADAM10 pharmacological inhibition on cortico-striatal dysfunction in Huntington’s disease

Chiara Zuccato, Elena Cattaneo, Paola Conforti, Chiara Cordiglieri et al.
Genetic Neurodegenerative Diseases
article

I023 Evaluating the impact of ADAM10 pharmacological inhibition on cortico-striatal dysfunction in Huntington’s disease

Chiara Zuccato, Elena Cattaneo, Paola Conforti, Chiara Cordiglieri, Andrea Scolz, Allegra Lenci
article en

Abstract

<h3>Background</h3> Cortico-striatal dysfunction is an early pathogenic event contributing to cognitive decline in Huntington’s disease (HD). A Disintegrin and Metalloproteinase Domain-Containing Protein 10 (ADAM10) is enriched in the brain and governs excitatory synapse structure and function by shedding neuronal trans-synaptic proteins. We have previously linked ADAM10 hyperactivity and enhanced proteolysis of N-Cadherin to HD synaptic dysfunction and cognitive decline. <h3>Aim</h3> Our aim is to evaluate whether the ADAM10 inhibitor GI254023X alleviates pre- and postsynaptic defects in the HD cortico-striatal circuitry. <h3>Methods</h3> A two-compartment microfluidic system was used, together with mouse primary cortical and striatal neurons from wild-type and HD mice, to reconstruct the cortico-striatal circuitry in vitro. Immunolabelling of pre- and post-synaptic proteins was used to identify excitatory synaptic contacts. Furthermore, live-imaging microscopy was employed to monitor Brain-Derived Neurotrophic Factor (BDNF) transport. Cortical and striatal neurons were exposed to GI254023X in acute and chronic paradigms. <h3>Results</h3> We recreated the wild-type and HD cortico-striatal circuitry in microfluidic chambers. We developed an automated pipeline to quantitatively evaluate excitatory synapse density. We set up conditions to study transport dynamics of BDNF-containing vesicles in the cortical afferents. We identified GI254023X doses and exposure times that conferred neuroprotection to HD neurons. Currently, we are testing if GI254023X restores BDNF transport in HD cortical neurons. <h3>Conclusion</h3> Our findings suggest that pharmacological inhibition of ADAM10 attenuates synaptic phenotypes in the HD cortico-striatal circuitry. Future studies will evaluate the therapeutic potential of GI254023X in rescuing synaptic and cognitive abnormalities in HD mice. Funded by Telethon Foundation (#GGP20067)

University of Milan (IT), Istituto Nazionale Genetica Molecolare (IT)
Zero hunger
Openalex Percentile: Top 85%
Genetic Neurodegenerative Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.